Long-term human interferon-β maintenance therapy for malignant gliomas

International Journal of Immunotherapy

Volumn 15, Issue 1, 1999, Pages 39-49

  Tanaka, S ^a   Taniura, S ^a   Watanabe, T ^a   Nagashima, T ^b   Hori, T ^c  

^a TOTTORI UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON RECEPTOR; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; MALE; MOLECULAR BIOLOGY; NATURAL KILLER CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032818034     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Nagai M. Clinical trials of human fibroblast interferon (HulFN-β) on malignant brain tumors. Nippon Gan Chiro Gakkai Shi, 18, 60, 1983 (in Japanese).
2. Nagai M., Arai T. Clinical effect of interferon in malignant brain tumors. Neurosurg. Rev., 7, 55, 1984.
3. Nagai M., Arai T., Watanabe K. Immunological state of patients with malignant glioma and its alteration by interferon therapy. Biotherapy (Tokyo), 2, 242, 1988 (in Japanese).
4. Takakura K., Nomura K. Relative survival rate. In: "Brain Tumor Registry of Japan". The committee of brain tumor registry of Japan, Tokyo, 1996, pp. 67 (in Japanese).
5. Yoshida J., Kajita Y., Wakabayashi T., Sugita K. Long-term follow up results of 175 patients with malignant glioma: Importance of radical tumor resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta. Neurochir. (Wien), 127, 55, 1994.
6. Tanaka S., Nagashima T., Matsuno A., Kamitani H., Ikawa E., Hori T. Efficacy of granulocyte-colony stimulating factor in adjuvant therapy of malignant brain tumors. Biotherapy (Tokyo), 10, 173, 1996 (in Japanese).
7. Tanaka S., Nagashima T., Manaka S., Hori T., Yasumoto S. Growth suppression and astrocytic differentiation of glioma cell lines by interleukin 1. J. Neurosurg., 81, 402, 1994.
8. Cook A.W., Carter W.A., Nidzgorski F., Akhtar L. Human brain tumor-derived cell lines: Growth rate reduced by human fibroblast interferon. Science, 219, 881, 1983.
9. Gresser I. Antitumor effects of interferon. Adv. Cancer Res., 16, 97, 1972.
10. Inoue I., Yoshida J., Kato K., Wakabayashi T., Kobayashi T., Kageyama N. Various immunological parameters studied in patients with malignant brain tumor. Neurol. Med. Chir. (Tokyo), 25, 168, 1985 (in Japanese).
11. Yates A.J., Stephens R.E., Elder R.J., Markowitz D.L., Rice J.M. Effects of interferon and gangliosides on growth of cultured human glioma and fetal brain cells. Cancer Res., 45, 1033, 1985.
12. Tanaka S., Murakami M., Hirakawa M., Manaka S., Nagashima T. Human Interferon β therapy for primitive neuroectodermal tumors: Case report. Neurol. Medico-Chirurgica, 35, 82, 1995.
13. Chomczynski P., Sacchi N. Single-step methods of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156, 1987.
14. Kawasaki E.S. Amplification of RNA. In: lnnis M.A., Gelfand D.H., Sninski J.J. (Eds.). "PCR Protocols, A Guide to Methods and Applications". Academic Press, San Diego, 1990, pp 21.
15. Tada M., Diserens A.-C., Desbaillets I., Tribolet N. Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J. Neurosurg., 80, 1063, 1994.
16. Guesdon J.L., Ternynck T., Avrameas S. The use of avidinbiotin interaction in immunoenzymatic techniques. J. Histochem. Cytochem., 27, 1131, 1979.
17. Tanaka S., Nagashima T., Nishihara T., Hori T. Endogenous tumor necrosis factor induction by interleukin 1 in nude mouse transplanted with human glioma. Int. J. Immunother., 12, 33, 1997.
18. Korosue K., Takeshita I., Mannoji H., Fukui M. Interferon effects on multiplication, cytoplasmic protein and GFAP content, and morphology in human glioma cells. J. Neuro-Oncol., 1, 69, 1983.
19. Hori T., Inoue Y., Hokama Y., Yamamoto F., Iwanaga M., Watanabe T. The effect of local injection of interferon against human malignant glioma transplanted into nude mice and the mechanism of its effect. Brain Nerve, 41, 911, 1989.
20. Nakamura O., Nomura K., Maruo K., Ueyama Y., Takakura K. Antineoplastic effect of Hu-IFN-β, and other anticancer drugs on malignant brain tumors in athymic nude mice. Neurological Surg., 13, 503, 1985 (in Japanese).
21. Joshi A.R., Sarkar F.H., Gupta S.L. Interferon receptors. J. Biol. Chem., 257, 13884, 1982.
22. Langer J.A., Pestka S. Interferon receptors, Immunol. Today, 9, 393, 1988.
23. Novick D., Cohen B., Rubinstein M. The human interferon α/β receptor: Characterization and molecular cloning. Cell, 77, 391, 1994.
24. Uze G., Lutfalla G., Gresser I. Genetic transfer of a functional human interferon receptor into mouse cells: Cloning and expression of its cDNA. Cell, 60, 225, 1990.
25. 125I mouse interferon to a specific cell surface receptor. Nature, 284, 459, 1980.
26. Colamonici O.R., Domanski P. Identification of a novel subunit of the type interferon receptor localized to human chromosome 21. J. Biol. Chem., 268, 10895, 1993.
27. Aguet M., Groebke M., Dreiding P. Various human interferon subclasses cross-react with common receptors: Their binding affinities with their specific biological activities. Virology, 132, 211, 1984.
28. Branca A.A., Baglioni C. Evidence that type and interferons have different receptors. Nature, 294, 768, 1981.
29. Platanias L.C., Colamonici O.R. Interferon induces rapid tyrosine phosphorylation of the subunit of its receptor. J. Biol. Chem., 268, 24053, 1992.
30. Harada H., Fujita T., Miyamoto M., et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible gene. Cell, 58, 729, 1989.
31. Miyamoto M., Fujita T., Kimura Y., et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β, gene regulatory elements. Cell, 54, 903, 1988.
32. Minks MA, Bemvom S., Maroney P.A., Baglioni C. Metabolic stability of 2′,5′ oligo(A) and 2′,5′ oligo(A)-dependent endonuclease in extracts of interferon-treated and control HeLa cells. Nucleic Acid Res., 6, 767, 1979,
33. Rosenblum M.G., Yung W.K.A., Kelleher P.J., Ruzicka F., Steck P.A., Borden E.G. Growth inhibitory effects of interferon-β but not interferon-α on human glioma cells: Correlation of receptor binding, 2′, 5′-oligoadenylate synthetase and protein kinase activity. J. Interferon Res., 10, 141, 1990.
34. Harada H., Kitagawa M., Tanaka N., et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factor-1 and -2. Science, 259, 971, 1993.
35. Harada H., Takahashi E., Itoh S., Harada K., Hori T., Taniguchi T. Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: Implications for a gene network in the interferon system. Mol. Cell Biol., 14, 1500, 1994.